Nautilus Biotechnology (NAUT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Nautilus Biotechnology

NasdaqCM•Healthcare•Biotechnology

$0.90-0.01(-0.02%)Market closed

Market Cap

$122.81M

P/S

646.4x

P/B

0.9x

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

How this company scores

AverageMetricSide Score: 40/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (8/25).

Profitability8/25

Growth9/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 646.4x5y range 646.4x – 646.4x

P/B · 0.9x5y range 0.5x – 3.0x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $122.81M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $190,000
Q. Revenue: $190,000
TTM EBITDA: $-14.38M
TTM Op. Income: $-15.76M
Q. Op. Income: $-15.76M
TTM Net Income: $-56.52M
Q. Net Income: $-14.47M
EPS: $-0.11
Shares Out.: $127.14M

$190,000 in TTM revenue grew from zero YoY, reaching $190,000 last quarter. TTM EBITDA of $-14.38M and TTM operating income of $-15.76M show growth is flowing through to the bottom line. However, net income is negative at $56.52M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 0% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 92.1%
EBITDA Margin: -8153.2%
Op. Margin: -8296.3%
Net Margin: -7615.3%

Op. margin of -8296.3% is down 8296.3% YoY — costs are rising relative to revenue. Net margin at -7615.3% and gross margin of 92.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 0% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 646.4x
P/B Ratio: 0.9x

P/S of 646.4x and P/B of 0.9x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $163.58M
Cash: $13.17M
Long-Term Debt: N/A
Book Value: $131.11M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-13.73M
TTM Free Cash Flow: $-51.86M
FCF Margin: -27295.3%
FCF / Net Income: 0.9

TTM FCF of $-51.86M on $-13.73M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 8% — a weakening trend.